New York State Common Retirement Fund Grows Holdings in Repligen Corporation (NASDAQ:RGEN)

New York State Common Retirement Fund grew its holdings in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 7.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 625,388 shares of the biotechnology company's stock after buying an additional 43,946 shares during the quarter. New York State Common Retirement Fund owned 1.11% of Repligen worth $79,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in RGEN. Proficio Capital Partners LLC purchased a new position in shares of Repligen during the 4th quarter valued at approximately $3,066,000. Swiss National Bank lifted its stake in Repligen by 0.9% during the fourth quarter. Swiss National Bank now owns 104,700 shares of the biotechnology company's stock worth $15,071,000 after purchasing an additional 900 shares during the last quarter. Natixis Advisors LLC lifted its stake in Repligen by 31.8% during the fourth quarter. Natixis Advisors LLC now owns 44,317 shares of the biotechnology company's stock worth $6,379,000 after purchasing an additional 10,692 shares during the last quarter. CBIZ Investment Advisory Services LLC bought a new position in Repligen during the fourth quarter worth $58,000. Finally, Polen Capital Management LLC lifted its stake in Repligen by 14.6% during the fourth quarter. Polen Capital Management LLC now owns 40,556 shares of the biotechnology company's stock worth $5,838,000 after purchasing an additional 5,173 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Monday, May 5th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a research report on Sunday, June 29th. Finally, JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a research report on Tuesday, April 29th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $170.75.

Repligen Price Performance

Shares of RGEN opened at $130.19 on Monday. The firm has a market capitalization of $7.31 billion, a price-to-earnings ratio of -289.31, a price-to-earnings-growth ratio of 3.73 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen Corporation has a one year low of $102.97 and a one year high of $182.52. The stock's fifty day moving average is $125.65 and its 200-day moving average is $139.29.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $0.28 earnings per share. Equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.